Intent to Apply (ITA)
A total of 16 eligible ITA forms were received. A breakdown of eligible ITA forms by disease, intervention and development stage is shown below:

- **Disease**
  - Malaria: 8
  - TB: 4
  - Leishmaniasis: 2
  - Dengue: 1
  - Chagas: 1

- **Intervention**
  - Drug: 10
  - Vaccine: 6
  - Diagnostics: 2

- **Development Stage**
  - Pre-clinical: 14
  - Clinical: 5

*One or more ITA included multiple diseases, interventions and/or development stages in the scope.*
Full Proposal
A total of 15 eligible proposals were received. A breakdown of eligible proposals by disease, intervention and development stage is shown below:* 

- Disease:
  - Malaria, 8
  - TB, 3
  - Leishmaniasis, 2
  - Dengue, 1
  - Chagas, 1

- Intervention:
  - Drug, 9
  - Vaccine, 6
  - Diagnostics, 1

- Development Stage:
  - Pre-clinical, 13
  - Clinical, 5

*One or more proposals included multiple diseases, interventions and/or development stages in the scope.
The following seven projects were awarded funding.

<table>
<thead>
<tr>
<th>Project Title</th>
<th>Collaboration Partners</th>
<th>Disease</th>
<th>Intervention</th>
<th>Development Stage</th>
<th>Total Amount</th>
</tr>
</thead>
</table>
| Development of a Live Attenuated Tetravalent Dengue Vaccine                  | 1. The Chemo-Sero-Therapeutic Research Institute (KAKETSUKEN)  
2. Center for Vaccine Development, Institute of Molecular Biosciences, Mahidol University | Dengue fever    | Vaccine      | Pre-Clinical (Lead Optimization-IND)        | ¥345,027,667       |
| Preclinical and clinical development of (+)-SJ000557733, a novel inhibitor of Plasmodium ATP4 | 1. St Jude Children's Research Hospital  
2. Eisai Co Ltd  
3. Medicines for Malaria Venture (MMV)                                                                                     | Malaria         | Drug         | Pre-Clinical (Lead Optimization-IND), Clinical (Ph1) | ¥376,892,206       |
| Lead optimization of a novel mechanism-of-action antimalarial               | 1. Broad Institute  
2. Eisai Co. Ltd                                                                                                                    | Malaria         | Drug         | Pre-Clinical (Lead Optimization-IND)        | ¥299,752,512       |
| Testing DSM265, a novel antimalarial acting through DHODH, in combination with OZ439 | 1. Medicines for Malaria Venture (MMV)  
2. Takeda Pharmaceutical Company Limited                                                                                              | Malaria         | Drug         | Clinical (Ph1)                             | ¥129,088,303       |
| Clinical development of the BK-SE36 malaria vaccine candidate               | 1. European Vaccine Initiative (EVI)  
2. Research Institute for Microbial Diseases (RIMD)  
3. Centre National de Recherche et de Formation sur le Paludisme (CNRFP)                                                        | Malaria         | Vaccine      | IND - Clinical (Ph1)                        | ¥99,999,999        |
| Accelerating Development of Transmission-Blocking Vaccines for Malaria Elimination Using a Novel Vaccine Candidate | 1. PATH Malaria Vaccine Initiative  
2. Ehime University                                                                                                                  | Malaria         | Vaccine      | Pre-Clinical (Lead Optimization-IND)        | ¥76,609,856        |
| Adjuvant Technologies to Advance Chagas Disease Vaccine Development         | 1. Sabin Vaccine Institute  
2. Baylor College of Medicine (BCM)  
3. Eisai Co. Ltd  
4. Aeras                                                                                                                              | Chagas disease  | Vaccine      | Pre-Clinical (Lead Optimization-IND)        | ¥200,000,000       |